Becton, Dickinson and Company (NYSE:BDX) Releases FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 14.750-15.050 for the period, compared to the consensus estimate of 14.850. The company issued revenue guidance of -, compared to the consensus revenue estimate of $22.8 billion.

Becton, Dickinson and Company Stock Up 0.3%

BDX opened at $177.88 on Friday. The business’s fifty day simple moving average is $186.77 and its 200 day simple moving average is $182.42. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market cap of $50.99 billion, a PE ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 71.36%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BDX. Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $203.50.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,249 shares of company stock worth $231,358. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth $352,000. Geneos Wealth Management Inc. increased its holdings in Becton, Dickinson and Company by 5.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 3,437 shares of the medical instruments supplier’s stock worth $592,000 after buying an additional 169 shares in the last quarter. Caxton Associates LLP purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth about $212,000. Headlands Technologies LLC bought a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $1,593,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Becton, Dickinson and Company by 20.9% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 325,867 shares of the medical instruments supplier’s stock valued at $56,195,000 after acquiring an additional 56,292 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.